Hamza Hassan MD
Hamza Hassan
MD
Assistant Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Bone Marrow Transplantation; Cardio-Oncology; Drug Development; Health Disparities Research; Medical Education Research; Monoclonal Antibodies; Oncology; Racial Disparities Health Research; Transcriptomics; Translational Research; Whole Genome Sequencing
Professional Summary:
I am a hematologist with a research focus on novel translational clinical trials focused on plasma cell dyscrasias. My current work involves understanding the biology of high-risk myeloma and amyloidosis and designing novel clinical trials to improve patient outcomes and QoL.
For me, caring for a cancer patient is more than treating a disease; it's a healing process involving both the patient's body, mind, and caregivers. I would like to see myself as a successful clinical and translational researcher, a compassionate physician, and a thought leader in the field of Multiple Myeloma and AL Amyloidosis.
Education and Training:
- MD, Medicine and Surgery, Rawalpindi Medical College/University of Health Sciences, Lahore, Cum Laude (2014)
Journal Articles:
- Itchaki G, Jarhovsky O, Castillo JJ, Hassan H, Gatt ML, Leiba M, Raanani P, Gertz MA, Vaxman I. (2024) Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review. Leukemia & lymphoma (Mar)1-7.
- DuMontier C, La J, Bihn J, Corrigan J, Yildirim C, Dharne M, Hassan H, Yellapragada S, Abel GA, Gaziano JM, Do NV, Brophy M, Kim DH, Munshi NC, Fillmore NR, Driver JA. (2023) More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood advances (Oct), 7(20): 6275-6284. doi:10.1182/bloodadvances.2023011019
- La J, DuMontier C, Hassan H, Abdallah M, Edwards C, Verma K, Ferri G, Dharne M, Yildirim C, Corrigan J, Gaziano JM, Do NV, Brophy MT, Driver JA, Munshi NC, Fillmore NR. (2023) Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiology and drug safety (May), 32(5): 558-566. doi:10.1002/pds.5579
- Edwards CV, Hassan H, Yildirim C, Ferri G, Verma KP, Murray Horwitz ME, Fillmore NR, Munshi NC. (2023) Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood advances (Feb), 7(4): 482-490. doi:10.1182/bloodadvances.2022008021
- Hassan H, Ammad Ud Din M, Jamshed S, Bress J, Mustafa SS. (2022) Effect of Ibrutinib on Hmphocytic Leukemia: a Single-Center Experience. Hematology/oncology and stem cell therapy (Dec), 15(4): 208-212.
- Hassan H, Verma K, Ferri G, Brauneis D, Quillen K, Sloan JM, Sanchorawala V, Edwards CV. (2022) Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Transplantation and cellular therapy (Nov), 28(11): 761.e1-761.e7.
- Hassan H, Anwer F, Javaid A, Hashmi H. (2021) Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis. Critical reviews in oncology/hematology (Sep), 165: 103435.
- Usman RM, Razzaq F, Akbar A, Farooqui AA, Iftikhar A, Latif A, Hassan H, Zhao J, Carew JS, Nawrocki ST, Anwer F. (2021) Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia-Pacific journal of clinical oncology (Jun), 17(3): 193-208.
- Hughes DM, DeMari S, Hassan H, Sanchorawala V, Sloan JM. (2021) Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clinical lymphoma, myeloma & leukemia (May), 21(5): e460-e463.
- Hassan H, Szalat R. (2021) Genetic Predictors of Mortality in Patients with Multiple Myeloma. The application of clinical genetics (Jan), 14: 241-254. doi:10.2147/TACG.S262866
- Majeed A, Sagar F, Latif A, Hassan H, Iftikhar A, Darouiche RO, Mohajer MA. (2019) Does antimicrobial coating and impregnation of urinary catheters prevent catheter-associated urinary tract infection? A review of clinical and preclinical studies. Expert review of medical devices (Sep), 16(9): 809-820.
- Mushtaq A, Iftikhar A, Hassan H, Lakhani M, Sagar F, Kamal A, Zahid U, Ali Z, Razzaq F, Zar MA, Hassan SF, Safdar A, Raychaudhuri S, Anwer F. (2019) Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. Clinical lymphoma, myeloma & leukemia (Jul), 19(7): 447-461.
- Iftikhar A, Hassan H, Iftikhar N, Mushtaq A, Sohail A, Rosko N, Chakraborty R, Razzaq F, Sandeep S, Valent JN, Kanate AS, Anwer F. (2019) Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies (Basel, Switzerland) (May), 8(2). doi:10.3390/antib8020034